← Back to Search

Unknown

CVL-231 for High Blood Pressure

Phase 1
Waitlist Available
Research Sponsored by Cerevel Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 84
Awards & highlights

Study Summary

This trial is testing a new medication to see if it lowers blood pressure and heart rate in people with stable schizophrenia.

Eligible Conditions
  • High Blood Pressure
  • Schizophrenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through day 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change from Baseline to Week 8 in the 24-hour ambulatory SBP (Systolic Blood Pressure)
Secondary outcome measures
Area under the plasma concentration-time curve over dosing interval (AUCτ) for CVL-231 and Metabolite (PF-06892787)
Frequency of clinically significant changes in clinical laboratory assessments
Frequency of clinically significant changes in electrocardiograms
+14 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: CVL-231 Dose Level 2Experimental Treatment1 Intervention
30 mg once daily
Group II: CVL-231 Dose Level 1Experimental Treatment1 Intervention
10 mg once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CVL-231
2022
Completed Phase 1
~300

Find a Location

Who is running the clinical trial?

Cerevel Therapeutics, LLCLead Sponsor
34 Previous Clinical Trials
5,544 Total Patients Enrolled
Erica Koenig, PhDStudy DirectorCerevel Therapeutics, LLC
3 Previous Clinical Trials
1,594 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
2022. "Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05245539.
~48 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top